Cerevel Therapeutics Holdings, Inc.
CERE
Rang in Aktien
#2803
Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical firm... Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing treatments for a range of neuroscience disorders. The company boasts a robust pipeline of therapeutic candidates currently undergoing various phases of clinical evaluation. Key assets include emraclidine, a positive allosteric modulator (PAM) in Phase 1b trials for schizophrenia. Another PAM, Darigabat, is being assessed in a Phase 2 proof-of-concept study for drug-resistant focal onset seizures in epilepsy, as well as in a Phase 1 trial for acute anxiety. For Parkinson's disease, Cerevel is advancing Tavapadon, a selective dopamine D1/D5 partial agonist, through Phase 3 clinical trials for both early and late stages of the condition. A related compound, CVL-871, also a selective dopamine D1/D5 partial agonist, is in Phase 2a trials for dementia-related apathy. The company's portfolio further includes CVL-936, a selective dopamine D3-preferring antagonist in Phase I for substance use disorder; CVL-354, a selective kappa-opioid receptor antagonist targeting major depressive disorder and substance use disorder; and CVL-047, a selective PDE4 inhibitor also aimed at major depressive disorder and substance use disorder. Beyond individual compounds, Cerevel is actively developing an M4 agonist program for psychosis and related indications, alongside an LRRK2 inhibitor program designed to address the progression of Parkinson's disease. Founded in 2018, Cerevel Therapeutics is headquartered in Cambridge, Massachusetts.
Aktienkurs
$44.96
Zuletzt synchronisiert: 2024-08-01
Marktkapitalisierung
$6.67B
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Cerevel Therapeutics Holdings, Inc. (CERE)
Kategorie
Healthcare
Gewinn für Cerevel Therapeutics Holdings, Inc. (CERE)
Gewinn im Mar 2024 TTM: $-459.91M
Laut den aktuellen Finanzberichten von Cerevel Therapeutics Holdings, Inc. betragen die aktuellen Gewinne des Unternehmens $-459.91M. Im Jahr 2022 erzielte das Unternehmen einen Gewinn von $-351.35M, ein Rückgang im Vergleich zu dem Gewinn im Jahr 2021, der $-225.33M betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von Cerevel Therapeutics Holdings, Inc. von 2012 bis 2026
Gewinn am Ende jedes Jahres
| Jahr | Gewinn | ändert |
|---|---|---|
| 2026 (TTM) | $-459.91M | 6.38% |
| 2023 | $-432.34M | 23.05% |
| 2022 | $-351.35M | 55.92% |
| 2021 | $-225.33M | 48.08% |
| 2020 | $-152.17M | 18.56% |
| 2019 | $-128.34M | -72.32% |
| 2018 | $-463.64M | 1,546.73% |
| 2015 | $-28.16M | -3.97% |
| 2014 | $-29.32M | -9.81% |
| 2013 | $-32.51M | 10.55% |
| 2012 | $-29.41M | 0.00% |
Gewinn ähnlicher Unternehmen oder Konkurrenten
| Unternehmen | Gewinn | Gewinnunterschied | Land |
|---|---|---|---|
| $5.27B | -1,246.94% |
US
|
|
| $-3.09B | 571.22% |
US
|
|
| $-4.02B | 773.25% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -524.14% |
NL
|
